UBS Group’s Immunogen Inc IMGN Stock Holding History

UBS Group’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,300	Closed	-$543K	–	10396
2023 Q4	$543K	Buy	18,300 +5,400	+42%	+$108K	﹤0.01%	5047
2023 Q3	$205K	Hold	12,900	–	–	﹤0.01%	5362
2023 Q2	$243K	Buy	+12,900	New	+$152K	﹤0.01%	5356
2015 Q3	–	Sell	-30,000	Closed	-$431K	–	8711
2015 Q2	$431K	Buy	+30,000	New	+$330K	﹤0.01%	4253
2015 Q1	–	Sell	-2,300	Closed	-$14K	–	9528
2014 Q4	$14K	Buy	+2,300	New	+$21K	﹤0.01%	8100

Other funds holding IMGN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's IMGN Position: Q1 2024 in Review

UBS Group sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 201,197 shares — an estimated $5.97M sold.

UBS Group first reported a position in IMGN in Q4 2014 and held it in 37 quarters. The position peaked at $5.97M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

UBS Group reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
UBS Group sold 201,197 Immunogen Inc shares in Q1 2024, an estimated $5.97M.
UBS Group first reported a position in Immunogen Inc in Q4 2014 and held it in 37 quarters.
UBS Group's Immunogen Inc position peaked at $5.97M in Q4 2023.
3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.